These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors. Shomali W; Gotlib J Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174 [TBL] [Abstract][Full Text] [Related]
9. Avapritinib in the Treatment of Systemic Mastocytosis: an Update. Below S; Michaelis LC Curr Hematol Malig Rep; 2021 Oct; 16(5):464-472. PubMed ID: 34580817 [TBL] [Abstract][Full Text] [Related]
10. Systemic mastocytosis with an associated hematologic neoplasm complicated by recurrent anaphylaxis: Prompt resolution of anaphylaxis with the addition of avapritinib. Kudlaty E; Perez M; Stein BL; Bochner BS; Kuang FL J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2534-2536. PubMed ID: 33677080 [No Abstract] [Full Text] [Related]
11. Advanced Systemic Mastocytosis with associated haematological neoplasm: Treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant. Sriskandarajah P; McLornan DP; Oni C; Wilson AJ; Woodley C; Ciesielska M; Raj K; Dillon R; Ethell M; Chacko J; Orchard K; Radia DH Curr Res Transl Med; 2023; 71(3):103398. PubMed ID: 37331225 [TBL] [Abstract][Full Text] [Related]
12. Avapritinib versus Placebo in Indolent Systemic Mastocytosis. Gotlib J; Castells M; Elberink HO; Siebenhaar F; Hartmann K; Broesby-Olsen S; George TI; Panse J; Alvarez-Twose I; Radia DH; Tashi T; Bulai Livideanu C; Sabato V; Heaney M; Van Daele P; Cerquozzi S; Dybedal I; Reiter A; Pongdee T; Barete S; Ustun C; Schwartz L; Ward BR; Schafhausen P; Vadas P; Bose P; DeAngelo DJ; Rein L; Vachhani P; Triggiani M; Bonadonna P; Rafferty M; Butt NM; Oh ST; Wortmann F; Ungerstedt J; Guilarte M; Taparia M; Kuykendall AT; Arana Yi C; Ogbogu P; Gaudy-Marqueste C; Mattsson M; Shomali W; Giannetti MP; Bidollari I; Lin HM; Sulllivan E; Mar B; Scherber R; Roche M; Akin C; Maurer M NEJM Evid; 2023 Jun; 2(6):EVIDoa2200339. PubMed ID: 38320129 [TBL] [Abstract][Full Text] [Related]
13. Clonal dynamics of aggressive systemic mastocytosis on avapritinib therapy. Huang X; Pomicter AD; Ahmann J; Qiao Y; Chen OS; George TI; Cruz-Rodriguez N; Guru SA; Marth GT; Deininger MW Blood Cancer J; 2024 Oct; 14(1):179. PubMed ID: 39402020 [No Abstract] [Full Text] [Related]
14. Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data. von Mehren M; Heinrich MC; Shi H; Iannazzo S; Mankoski R; Dimitrijević S; Hoehn G; Chiroli S; George S BMC Cancer; 2021 Mar; 21(1):291. PubMed ID: 33740926 [TBL] [Abstract][Full Text] [Related]
15. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis. Reiter A; George TI; Gotlib J Blood; 2020 Apr; 135(16):1365-1376. PubMed ID: 32106312 [TBL] [Abstract][Full Text] [Related]